Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free PVLA Stock Alerts

Palvella Therapeutics (PVLA) Competitors

Palvella Therapeutics logo
$138.77 +7.43 (+5.66%)
Closing price 04:00 PM Eastern
Extended Trading
$138.62 -0.15 (-0.11%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

PVLA vs. PRAX, IONS, SYRE, ALKS, and IMVT

Should you buy Palvella Therapeutics stock or one of its competitors? Palvella Therapeutics's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Ionis Pharmaceuticals (IONS), Spyre Therapeutics (SYRE), Alkermes (ALKS), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Palvella Therapeutics compare to Praxis Precision Medicines?

Palvella Therapeutics (NASDAQ:PVLA) and Praxis Precision Medicines (NASDAQ:PRAX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Palvella Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palvella Therapeutics$42.81M44.21-$41.72M-$4.83N/A
Praxis Precision Medicines$8.55M860.62-$303.27M-$12.93N/A

Palvella Therapeutics presently has a consensus price target of $209.14, suggesting a potential upside of 59.24%. Praxis Precision Medicines has a consensus price target of $613.26, suggesting a potential upside of 132.69%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Praxis Precision Medicines
2 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
3 Strong Buy rating(s)
2.95

Praxis Precision Medicines' return on equity of -34.15% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Palvella TherapeuticsN/A -47.84% -38.33%
Praxis Precision Medicines N/A -34.15%-32.42%

In the previous week, Praxis Precision Medicines had 7 more articles in the media than Palvella Therapeutics. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 0 mentions for Palvella Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.24 beat Palvella Therapeutics' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Overall Sentiment
Palvella Therapeutics Neutral
Praxis Precision Medicines Neutral

Palvella Therapeutics has a beta of -0.27, indicating that its share price is 127% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.79, indicating that its share price is 179% more volatile than the broader market.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Palvella Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Palvella Therapeutics compare to Ionis Pharmaceuticals?

Palvella Therapeutics (NASDAQ:PVLA) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Palvella Therapeutics. MarketBeat recorded 4 mentions for Ionis Pharmaceuticals and 0 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.00 beat Ionis Pharmaceuticals' score of -0.42 indicating that Palvella Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Palvella Therapeutics Neutral
Ionis Pharmaceuticals Neutral

Palvella Therapeutics has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Palvella Therapeutics' return on equity of -47.84% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Palvella TherapeuticsN/A -47.84% -38.33%
Ionis Pharmaceuticals -64.76%-111.08%-17.41%

Palvella Therapeutics presently has a consensus price target of $209.14, indicating a potential upside of 59.24%. Ionis Pharmaceuticals has a consensus price target of $89.20, indicating a potential upside of 106.00%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Ionis Pharmaceuticals
1 Sell rating(s)
4 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.73

Palvella Therapeutics has a beta of -0.27, suggesting that its stock price is 127% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Palvella Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palvella Therapeutics$42.81M44.21-$41.72M-$4.83N/A
Ionis Pharmaceuticals$944M7.62-$381.39M-$3.46N/A

Summary

Ionis Pharmaceuticals beats Palvella Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Spyre Therapeutics' return on equity of -30.74% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -30.74% -22.23%
Palvella Therapeutics N/A -47.84%-38.33%

Spyre Therapeutics currently has a consensus target price of $109.71, suggesting a potential upside of 37.31%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 59.24%. Given Palvella Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Palvella Therapeutics is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spyre Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.27, suggesting that its share price is 127% less volatile than the broader market.

In the previous week, Spyre Therapeutics had 29 more articles in the media than Palvella Therapeutics. MarketBeat recorded 29 mentions for Spyre Therapeutics and 0 mentions for Palvella Therapeutics. Spyre Therapeutics' average media sentiment score of 0.27 beat Palvella Therapeutics' score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Spyre Therapeutics Neutral
Palvella Therapeutics Neutral

Palvella Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre TherapeuticsN/AN/A-$155.20M-$1.95N/A
Palvella Therapeutics$42.81M44.21-$41.72M-$4.83N/A

Summary

Spyre Therapeutics beats Palvella Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Palvella Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alkermes presently has a consensus target price of $54.47, indicating a potential upside of 35.80%. Palvella Therapeutics has a consensus target price of $209.14, indicating a potential upside of 59.24%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Palvella Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.74
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

In the previous week, Alkermes had 7 more articles in the media than Palvella Therapeutics. MarketBeat recorded 7 mentions for Alkermes and 0 mentions for Palvella Therapeutics. Alkermes' average media sentiment score of 0.52 beat Palvella Therapeutics' score of 0.00 indicating that Alkermes is being referred to more favorably in the media.

Company Overall Sentiment
Alkermes Positive
Palvella Therapeutics Neutral

Alkermes has a net margin of 3.96% compared to Palvella Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes3.96% 4.15% 2.19%
Palvella Therapeutics N/A -47.84%-38.33%

Alkermes has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B4.56$241.66M$0.38105.55
Palvella Therapeutics$42.81M44.21-$41.72M-$4.83N/A

Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.27, meaning that its stock price is 127% less volatile than the broader market.

Summary

Alkermes beats Palvella Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Palvella Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Immunovant had 7 more articles in the media than Palvella Therapeutics. MarketBeat recorded 7 mentions for Immunovant and 0 mentions for Palvella Therapeutics. Immunovant's average media sentiment score of 0.69 beat Palvella Therapeutics' score of 0.00 indicating that Immunovant is being referred to more favorably in the media.

Company Overall Sentiment
Immunovant Positive
Palvella Therapeutics Neutral

Immunovant has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market.

Palvella Therapeutics' return on equity of -47.84% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -69.59% -62.49%
Palvella Therapeutics N/A -47.84%-38.33%

Immunovant currently has a consensus target price of $44.00, suggesting a potential upside of 45.41%. Palvella Therapeutics has a consensus target price of $209.14, suggesting a potential upside of 59.24%. Given Palvella Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Palvella Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Palvella Therapeutics has higher revenue and earnings than Immunovant. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$505.61M-$2.82N/A
Palvella Therapeutics$42.81M44.21-$41.72M-$4.83N/A

47.1% of Immunovant shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Palvella Therapeutics beats Immunovant on 9 of the 15 factors compared between the two stocks.

Get Palvella Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PVLA vs. The Competition

Export
MetricPalvella TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.00B$3.89B$7.19B$13.28B
Dividend YieldN/A3.65%2.53%16.36%
P/E Ratio-28.7313.54274.4726.16
Price / Sales46.711,185.17585.0081.25
Price / CashN/A117.6076.8253.72
Price / Book58.8017.1811.216.34
Net Income-$41.72M-$22.69M$3.50B$381.90M
7 Day Performance4.76%-1.17%-0.83%-1.36%
1 Month Performance-8.31%-9.68%-5.42%-4.29%
1 Year Performance97.99%10.04%4.36%-0.33%

Palvella Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PVLA
Palvella Therapeutics
1.8211 of 5 stars		$138.77
+5.7%		$209.14
+50.7%		+75.5%$2.00B$42.81MN/A29
PRAX
Praxis Precision Medicines
2.4206 of 5 stars		$263.55
-5.2%		$613.26
+132.7%		+385.4%$7.36B$8.55MN/A168
IONS
Ionis Pharmaceuticals
3.5253 of 5 stars		$43.30
-1.9%		$89.20
+106.0%		-38.1%$7.20B$944MN/A1,402
SYRE
Spyre Therapeutics
2.5491 of 5 stars		$79.90
-1.2%		$109.71
+37.3%		+351.9%$7.03B$890KN/A112
ALKS
Alkermes
3.1971 of 5 stars		$40.11
-3.2%		$54.47
+35.8%		+27.3%$6.73B$1.48B105.562,050

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:PVLA) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel